Fresh analysis suggests that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds far faster than those who end conventional diet and exercise regimens.
Published data in a major health publication points out that while obese people frequently drop a large proportion of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Users purchasing these medications must be cognizant of the risk of rapid weight regain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment mass within about a year and a half.
Comparing Treatments
The study, which looked at dozens of trials involving thousands of participants, compared the effects of GLP-1 agonists with conventional dieting.
Scientists emphasize that individuals who lose weight through dieting typically see a slower creep back—around 100 grams monthly—once they finish.
Explaining the Quick Rebound
Nutrition scientists suggest the mechanism of the drugs explains the accelerated weight return.
The injections imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone levels far above than normal might result in the body to produce less of its own natural GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making binge eating far more likely."
A Lifelong Issue?
The NHS recommend the injections for people with weight-linked health risks, accompanied by recommended lifestyle changes.
A number of clinicians argue that, considering the significant potential of relapse, the therapy is often long-term.
This perspective is echoed by pharmaceutical companies, who say that the results "emphasize the long-term nature of excess weight," comparing it to managing conditions like diabetes.
User Accounts
People who have discontinued the medication describe a intense return of cravings.
"It felt as if a trigger that goes on and I was suddenly ravenous," recalled one woman.
This challenge is worsened if individuals have not adopted sustainable dietary or behavioural changes during treatment.
Growing Interest
Recent estimates indicate that millions of adults in the UK have used these injections in the past year, with desire remaining high.
- Use is more common among women than males.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the drugs through private prescriptions rather than public health services.
Finally, researchers caution that while these medications are potent agents for weight loss, they are not a permanent fix and maintained weight loss hinges on combined behavioural management.
